ANLN and ECT2 mRNA expression was shown to be significantly overexpressed in tumors and under-expressed in normal tissue (|log2 fold change| > 1, p < 0.05) in the TCGA PRAD cohort. Here, ECT2 is linked to prostate adenocarcinoma.